DSIP

🔹 What is DSIP?  (Delta Sleep Inducing Peptide)

Class: Endogenous neuropeptide—short peptide (tridecapeptide, 9–13 amino acids) naturally produced in the brain and other tissues. First isolated in rabbits; a similar peptide is found in high concentrations in human milk. Mechanism: Modulates sleep architecture, reduces stress-related hormone activity (cortisol), and may influence thermoregulation, pain perception, and mood. Thought to interact with GABAergic and other neurotransmitter systems to promote slow-wave (deep) sleep. Also acts as an anticonvulsant, attenuates corticotrophin releasing factor at the pituitary gland, and decreases excitotoxicity through its influence on NMDA-subtype glutamate receptors. DSIP crosses the blood-brain barrier and follows a diurnal (day/night) secretion pattern, consistent with its role in sleep regulation. It has a short half-life of just 7–8 minutes. Primary focus: Sleep quality improvement (especially deep sleep), stress reduction, recovery enhancement, potential analgesic and mood-stabilizing effects, and mild neuroprotective properties. Molecular profile: Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. MW 849.

---

🔹 Oral Dosage (least common) Range studied/used in research: Oral bioavailability is extremely low; oral administration is largely ineffective. Typical protocol: No formal oral dosing exists; subcutaneous or intranasal routes are preferred. Notes: Peptide degradation in the GI tract makes oral use largely impractical.

---

🔹 Injectable / Sublingual / Intranasal Dosage (most common) Range: Commonly used at 100–500 µg per dose subcutaneously, intranasally, or sublingually. Some protocols use 1 mg/day split into multiple doses. Frequency: Typically 1–2 times daily, with evening dosing favored to align with sleep cycles. Real-world example: A common compounding pharmacy protocol uses a 1000 mcg/ml vial dosed at 100 mcg subcutaneously nightly, used as-needed for sleep. Rationale: Direct administration ensures central nervous system access and reliable modulation of sleep-related pathways.

---

🔹 Cycle Length Common cycle length: 2–6 weeks is often reported for sleep optimization or recovery purposes. Off-cycle: Breaks of 1–2 weeks may be used to evaluate tolerance or avoid receptor desensitization. Note: Limited human research; durations are primarily based on anecdotal and animal studies.

---

🔹 Optimal Dosing Window Injectable / Sublingual / Intranasal: Evening or shortly before bedtime is preferred to promote deep sleep. Avoid daytime dosing unless aiming for stress modulation or recovery support.

---

✅ Educational Integration Example (injectable / intranasal) Example protocol: 250 µg subcutaneous injection or intranasal dose 30–60 minutes before bedtime for 4 weeks. Pair with: Sleep hygiene practices, magnesium or GABA support, and stress management for maximal deep sleep enhancement.

---

🔹 Stacking Strategy (Educational) Since DSIP primarily targets sleep, stress modulation, and recovery, stacking focuses on enhancing restorative processes and overall recovery: 🔸 Sleep & Recovery Support

• Melatonin or Circadian modulators: Complement DSIP’s sleep-promoting effects.
• Magnesium, GABA, or L-Theanine: Support relaxation and deeper sleep cycles.

🔸 Stress & Mood Optimization

• Adaptogens (Rhodiola, Ashwagandha): Reduce cortisol and support stress resilience.
• BPC-157 or TB-500: Promote tissue repair during enhanced sleep recovery.

🔸 Longevity / Regenerative Health

• NAD⁺ precursors (NMN/NR): Support cellular repair and recovery during deep sleep phases.
• Quality nutrition and exercise: Enhance recovery and GH release during sleep.

Disclaimer: Do not rely on any dosing information provided, this is for educational and research only. Always double and triple check alternative references for education. Please consult with healthcare provider for your specific dosing and protocol if applicable.